Monday, February 10, 10:30 a.m. - 11:25 a.m. | Jade
Investing in the RNA space? What delivery technology will win the race to turn these novel molecules into approved therapies? Is there a “winner take all” in this space or does each type of nucleic acid technology require a unique platform for delivery? This panel will discuss ongoing innovation in the nanoparticle, liposomal, nucleic acid, and conjugate-based approaches to delivering one of the most promising modalities in biotech.
- Thomas Wei, Senior Research Analyst, Biotechnology, Jefferies LLC
- Douglas Fambrough, PhD, CEO, Dicerna Pharmaceuticals
- Bruce Given, MD, Chief Operating Officer, Arrowhead Research Corporation
- Barry Greene, President & Chief Operating Officer, Alnylam Pharmaceuticals
- Kleanthis G. Xanthopoulos, PhD, President & CEO, Regulus Therapeutics
Douglas Fambrough, PhD
Dr. Douglas Fambrough co-founded Dicerna in 2007 and currently serves as the Company’s chief executive officer. Prior to taking the CEO role at Dicerna, Dr. Fambrough was a General Partner with the Boston-based life science venture capital firm Oxford Bioscience Partners where for 10+ years he specialized in financing innovative life science technology companies. His investments include first generation RNA Interference pioneer Sirna Therapeutics, organized by Dr. Fambrough and two other investors in 2000, and where he served on their Board of Directors until the company was acquired by Merck for $1.1 billion in 2006. Other investments include Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for $600 million; and Cambrios Technologies, which invented and now markets biologically-inspired electronic materials for touch screens and flat panel displays. Before joining Oxford, he was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).
Dr. Fambrough graduated from Cornell University and obtained his Ph.D. in Genetics at the University of California, Berkeley.
Bruce Given, MD
Dr. Given has served as COO of Arrowhead Research, Inc (Nasdaq: ARWR) since October, 2011. Dr. Given retired as Chairman of the Board for ICON, plc (Nasdaq: ICLR) in 2013 and was CEO of Leonardo Biosystems from 2010 to 2013. Until June of 2007, Dr. Given served as President and Chief Executive Officer and as a member of the Board of Directors of Encysive Pharmaceuticals, which he joined in 2002. Prior to joining Encysive Pharmaceuticals, he was with Johnson & Johnson for 9 years, serving in several capacities including as President, International, Ortho-Clinical Diagnostics and as Group Vice President, Head of U.S. Marketing & Sales, Research & Development for Janssen Pharmaceutica. He has held various executive and senior management positions at Sandoz Pharma Ltd., Sandoz Research Institute and Schering-Plough Corporation. Prior to entering the pharmaceutical industry, he was on the medical faculty at the University of Chicago.
Dr. Given obtained his bachelor of sciences degree from Colorado State University, graduating Phi Beta Kappa. He received his M.D. degree with honors from the University of Chicago, Pritzker School of Medicine and completed his medical training at the University of Chicago and at Brigham and Women’s Hospital in Boston, where he was a Clinical Fellow at Harvard Medical School. He was board certified in internal medicine and endocrinology and metabolism and has authored 33 scientific publications.
In addition to his work with Leonardo and Arrowhead, Dr.Given serves on the Boards of Directors for Calando Pharmaceuticals, Pulmotect, for BioHouston, where he is Secretary of the Executive Committee of the Board and is a member of the inCube Scientific Advisory Board. He previously served as a member of the CPRIT Commercialization Committee, the Texas Life Sciences Committee, the Technology Review Committee of MD Anderson Medical Center, and is past Chairman of the Rider University Scientific Advisory Board.
Barry Greene joined Alnylam in 2003, and brings over 20 years of experience in healthcare, pharmaceutical, and biotechnology industries. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADE™(bortezomib) in mid 2003. Prior to joining Millennium in February 2001, Barry served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, his past experiences include Vice President of Marketing and Customer Services for AstraZeneca formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post merger integration; and Partner, Andersen Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. Barry received his B.S. in Industrial Engineering from University of Pittsburgh and serves as Senior Scholar at Duke University, Fuqua School of Business. Barry also serves on the Board of Acorda Therapeutics, Inc.
Kleanthis G. Xanthopoulos, PhD
Kleanthis G. Xanthopoulos, Ph.D. is a serial entrepreneur whose passion is building companies focused on innovation. Dr. Xanthopoulos has over 15 years in the biotechnology and pharmaceutical research industries as an executive, company founder, chief executive officer, investor and board member. Dr. Xanthopoulos has introduced two life science companies to NASDAQ and has brokered numerous creative strategic alliance and partnership deals with large pharmaceutical partners.
Dr. Xanthopoulos has served as President and Chief Executive Officer of Regulus Therapeutics Inc. [NASDAQ: RGLS] since joining the company in connection with its formation in 2007. Prior to that, he was a managing director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. from its inception in 2000 to 2006, and remained a Director until its acquitision by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals, Inc.) from 1997 to 2000. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.
Dr. Xanthopoulos is a member of the board of directors of the Biotechnology Industry Organization (BIO) and Zosano Pharma, Inc., co-founder and a member of the board of directors of Sente Inc., and is chairman of the board of directors of Apricus Biosciences (NASDAQ: APRI).
Thomas Wei joined Jefferies in October 2009 from Piper Jaffray, where he spent six years as a Managing Director in the biotechnology research group. Previously, he was at Deutsche Bank and Adams, Harkness & Hill, where he spent five years as an associate analyst in biotechnology. His prior therapeutic focuses have included HIV, infectious diseases, diabetes, obesity, inflammatory/autoimmune disorders and cancer. Mr. Wei received an AB degree in Biochemical Sciences from Harvard College and a MBA from Oxford University, where he was a Rhodes Scholar.